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Pfizer Oncology, New London, CT, USA Background: CP-751,871 is a fully human, IgG2 monoclonal antibody against the Insulin Growth Factor I Receptor (IGF-IR) active in preclinical models of NSCLC. We report the results of an ongoing phase Ib/II study in ten centers evaluating the safety and efficacy of the combination of paclitaxel (T), carboplatin (C) and CP-751,871 (I) in advanced NSCLC. Methods: Phase Ib was an open-label dose-escalation study of T (200 mg/m 2 ), C (AUC of 6) and CP-751,871 (0.05-10 mg/kg) every 3 weeks for up to 6 cycles in patients with advanced solid malignancies; pts with response or stable disease could receive extended CP-751,871 therapy. The ongoing phase II is an open label, randomized (2:1), non-comparative study of TCI versus TC alone. Only treatment-naïve NSCLC pts (stage IIIB or IV) are eligible in phase II. The statistical hypotheses are 28% (null) versus 40% -response of interest (RR) -for TCI.
Results:
Following informed consent and screening, 7 cohorts with a total of 30 pts, including 23 NSCLC pts, were enrolled in phase 1b. No dose limiting toxicities were identified and the recommended phase 2 dose cohort of 10 mg/kg was extended to 12 pts. One case of isolated grade 3 GGT elevation attributed to CP-751,871 was reported. An interim analysis for futility has been conducted at 73 pts enrolled in phase II: 48 treated with TCI; 25 with TC. TCI was well tolerated. All causality grade 3, 4 toxicity included (TCI, TC): hyperglycemia (20%, 10%), fatigue (15%, 8%), neutropenia (13%, 20%) and neuropathy (10%, 4%).Twenty-two pts receiving TCI (46%) and 8 pts on TC alone (32%) had objective responses. Furthermore, 14 out of 27 TCI pts (52%) with non-adenocarcinoma responded to treatment. In addition, a PR was observed in 1 out of 4 TC pts who elected to receive single agent I after progression on TC alone. Conclusions: CP-751,871 appears safe in combination with TC. Interim TCI activity has warranted further investigation. An additional 83 pts will be enrolled in phase II to assess further the safety and efficacy of this treatment combination in NSCLC. AstraZeneca, Osaka, Japan Background: Vandetanib (ZACTIMA™; ZD6474) is a once-daily, oral anticancer drug that selectively inhibits vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and RET (REarranged during Transfection) receptor tyrosine kinase activity. Vandetanib was evaluated as a monotherapy in a randomized, double-blind, dose-finding study in Japan. Methods: Eligible patients had locally advanced or metastatic (stage IIIB/IV) or recurrent NSCLC, after failure of one or two platinumbased chemotherapy regimens. Patients were randomized to receive once-daily oral vandetanib 100, 200 or 300 mg (1:1:1), with stratification according to sex, histology (adenocarcinoma vs other histology) and smoking status (smoker vs non-smoker). Tumor response was assessed by RECIST every 4 weeks for the first 24 weeks of treatment and then every 8 weeks until progressive disease (PD) or any other withdrawal criteria was met. The primary objective was to determine the objective response rate (ORR) for each vandetanib dose. Secondary assessments included disease control rate (DCR), safety and tolerability. Exploratory assessments included analysis of tumor samples for amplification of EGFR gene copy number (fluorescence in situ hybridization [FISH] ) and somatic mutations of the EGFR gene, and measurement of plasma VEGF levels. Results: Fifty-three patients (34 males/19 females, median age 60 years, range 30-78) received vandetanib (100 mg, n=17; 200 mg, n=18; 300 mg, n=18). The overall ORR was 13.2% (7/53; all partial responses [PRs] ). The ORR in the vandetanib 100, 200 and 300 mg/day arms were 17.6% (3/17), 5.6% (1/18) and 16.7% (3/18), respectively. There th World Conference on Lung Cancer was no observed trend in patient characteristics for the PRs except that all had adenocarcinoma histology. The DCR (PR or stable disease [SD] ≥8 weeks) in the vandetanib 100, 200 and 300 mg/day arms were 47.1%, 38.9% and 61.1%, respectively. The adverse event (AE) profile was consistent with that observed in previous studies of vandetanib in NSCLC; the most common AEs were rash (53%), diarrhea (51%), hypertension (47%) and asymptomatic QTc prolongation (40%). There was one fatal case of interstitial lung disease, which was reported 8 days after vandetanib 300 mg was discontinued because of PD. EGFR gene amplification analysis revealed 4/12 patients were FISH positive (SD and PD, both n=2) and 8/12 were FISH negative (PR, n=1; SD, n=3; and PD, n=4). Tumors from 27 patients were evaluated for EGFR mutations: confirmed mutation (n=1; exon 19 deletion [746-750]); confirmed no mutation (n=21); unconfirmed (n=5). The mutation-positive patient was a female non-smoker with FISH-positive adenocarcinoma and a best response of PD. Among the three PRs evaluated, two had no EGFR mutation and one had an unconfirmed result. Although patient numbers are small, baseline plasma VEGF levels (mean ± SE) appeared to be lower in patients who experienced clinical benefit following vandetanib treatment: PR (68.3 ± 40.4 pg/mL, n=6) and SD (50.5 ± 13.3 pg/mL, n=16) versus PD (128 ± 39.5 pg/mL, n=23).
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Conclusions:
In Japanese patients with refractory NSCLC, vandetanib monotherapy (100-300 mg/day) demonstrated antitumor activity with an acceptable safety and tolerability profile. The possible relationship between plasma VEGF levels and clinical outcome requires further investigation. Bevacizumab (Bv) in combination with carboplatin/paclitaxel received FDA approval in October 2006 for improving response rates and survival in first-line treatment of advanced NSCLC patients without brain metastases. Brain metastases were excluded based on a grade 3 intracerebral hemorrhage from a hepatocellular carcinoma brain metastasis in the original phase I study. Since NSCLC is the most common cause of brain metastases, a large fraction of patients who might benefit from Bv have never been evaluated formally. We report here on the safety of Bv therapy in 24 subjects with NSCLC following local therapy for brain metastases. Methods: Subjects were treated on protocols AVF3671g (ATLAS) or AVF3752g (PASSPORT): The ATLAS phase III study includes platinum based chemotherapy with Bv, followed by Bv ± erlotinib (E) to disease progression, for subjects with advanced or metastatic non-squamous NSCLC. Brain metastases subjects had to have completed whole brain radiotherapy (WBRT). The PASSPORT phase II study includes Bv combined with first-line or second-line systemic therapy in subjects with non-squamous NSCLC with treated brain metastases. Treatment for Brain metastases included radiosurgery, neurosurgery or WBRT.
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Demographic characteristics, baseline disease characteristics, prior treatment, and on-study treatment are summarized by study. The overall rate of CNS hemorrhage and exact 95% confidence interval using the method of Blyth-Still-Casella are reported. The mean number of Bv doses (15 mg/kg/q3w) in the 24 treated subjects was 4 and the median was 3 (range 1-15). 2 subjects were never treated with Bv. There were no CNS hemorrhages reported on either study (95 % upper confidence limit: 12.6%). On ATLAS, no subjects experienced Grade 3/4 CNS events. One onstudy death due to disease progression occurred while the subject was on the study treatment follow-up period. On PASSPORT, 2 subjects experienced new onset Grade 3 CNS events of seizures. One of these 2 subjects was not treated with Bv; the other had residual resolving hemorrhage at baseline prior to study treatment. Conclusions: These preliminary data are encouraging with respect to safe administration of bevacizumab to subjects with treated brain metastases in these two ongoing studies. It is anticipated that data on 40 subjects will be available at presentation; additional follow-up and subjects are necessary to more precisely characterize the CNS hemorrhage rate and overall safety of Bv treatment in this setting.
